Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Non-Current Liabilities (2016 - 2025)

IGC Pharma has reported Other Non-Current Liabilities over the past 14 years, most recently at $16000.0 for Q1 2025.

  • Quarterly Other Non-Current Liabilities fell 20.0% to $16000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $16000.0 through Mar 2025, down 20.0% year-over-year, with the annual reading at $16000.0 for FY2025, 20.0% down from the prior year.
  • Other Non-Current Liabilities was $16000.0 for Q1 2025 at IGC Pharma, roughly flat from $16000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $21000.0 in Q1 2023 and troughed at $15000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $16000.0 (2022), against an average of $17058.8.
  • Year-over-year, Other Non-Current Liabilities soared 31.25% in 2023 and then dropped 20.0% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $15000.0 in 2021, then changed by 0.0% to $15000.0 in 2022, then increased by 13.33% to $17000.0 in 2023, then decreased by 5.88% to $16000.0 in 2024, then changed by 0.0% to $16000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Non-Current Liabilities are $16000.0 (Q1 2025), $16000.0 (Q4 2024), and $20000.0 (Q3 2024).